ロード中...
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis. Immunotherapy with agents that target the PROGRAMMED DEATH 1 (PD-1) receptor have demonstrated clinical activity with durable responses in ear...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4914357/ https://ncbi.nlm.nih.gov/pubmed/26848626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7177 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|